Choose a language and wait for the translated text.
Shots:
Nimbus Therapeutics has dosed the first subjects in the P-I trial evaluating NDI-225673 (oral, highly selective SIK2 inhibitor) as SAD & MAD in healthy volunteers, assessing safety, tolerability, PK & PD
In preclinical studies, selective SIK2 inhibition suppressed TNFα, IL-6, IL-23 & IL-1β while increasing IL-10 & tissue-repair mediators (AREG, THBS1), and reduced disease activity in mouse colitis & arthritis models
NDI-225673 is designed to target SIK2 while sparing SIK1 & SIK3, with potential across immune-mediated inflammatory diseases in gastroenterology, rheumatology & dermatology
Ref: Nimbus Therapeutics | Image: Nimbus Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Nimbus Therapeutics Doses First Subjects in P-I Trial of NDI-225673 for Immune-Mediated Inflammatory Diseases appeared first on PharmaShots.
